Internal Medicine, Pulmonary Disease · Tallahassee, FL
NPI
1568487759
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1607 Saint James Ct Ste 2
Tallahassee, FL, 32308
Phone (850) 878-8714
Groups this clinician bills Medicare through
Medicare paid, 2024
$125K
1,102 services
Medicare patients, 2024
440
Average age 76
Drug cost, 2024
$1.3M
834 prescriptions
Company payments, 2025
$1,009
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David Y Huang was code 99233 (hospital e&m - subsequent), 401 times for 195 patients. In total David Y Huang billed 1,102 services in 44 codes, and Medicare paid $125K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-03-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 401 | 195 | $98.77 | $40K |
| 99291 Critical Care E&M | Facility | 252 | 111 | $179.18 | $45K |
| 99214 Office E&M - Established | Office | 88 | 81 | $100.31 | $8,827 |
| 99223 Hospital E&M - Initial | Facility | 81 | 80 | $140.73 | $11K |
| 99215 Office E&M - Established | Office | 49 | 37 | $148.56 | $7,279 |
| 94729 Pulmonary Function Testing | Office | 28 | 27 | $44.00 | $1,232 |
| 99232 Hospital E&M - Subsequent | Facility | 26 | 19 | $66.46 | $1,728 |
| 94726 Pulmonary Function Testing | Office | 22 | 22 | $43.33 | $953 |
| 94060 Pulmonary Function Testing | Office | 17 | 17 | $29.78 | $506 |
| 94375 Pulmonary Function Testing | Office | 14 | 13 | $30.38 | $425 |
| 94729 Pulmonary Function Testing | Facility | 11 | 11 | $7.37 | $81.07 |
By year: 2022 $139K for 1,356 services; 2023 $153K for 1,598 services; 2024 $125K for 1,102 services.
Medicare prescription drug claims, 2024
In 2024, the drug David Y Huang prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 144 prescriptions and refills. In total David Y Huang wrote 834 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 144 | 154 | 29 | $97K |
| Prednisone Generic | 72 | 96 | 22 | $277 |
| Eliquis Apixaban | 51 | 71 | Under 11 | $41K |
| Modafinil Generic | 44 | 72 | Under 11 | $3,927 |
| Gabapentin Generic | 38 | 47 | Under 11 | $153 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 28 | 40 | 15 | $855 |
| Sodium Oxybate Generic | 27 | 27 | Under 11 | $493K |
| Azithromycin Generic | 23 | 23 | 15 | $99.8 |
| Montelukast Sodium Generic | 22 | 34 | Under 11 | $222 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 21 | 21 | Under 11 | $393 |
| Breo Ellipta Fluticasone/Vilanterol | 21 | 21 | Under 11 | $7,729 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 18 | 32 | Under 11 | $147 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 18 | 18 | Under 11 | $11K |
| Ventolin Hfa Albuterol Sulfate | 18 | 19 | Under 11 | $982 |
| Fluticasone Propionate Generic | 17 | 35 | Under 11 | $281 |
Brand drugs: 445 claims; generic drugs: 389 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David Y Huang $1,009 ($1,009 in general payments such as food, travel and fees) from 20 companies. The largest payer was GlaxoSmithKline, LLC. with $199.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 9 | $199 |
| Ethicon Inc. JNJ | 1 | $141 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $107 |
| ANI Pharmaceuticals, Inc. ANIP | 2 | $56.42 |
| Stryker Corporation SYK | 1 | $46.63 |
| Lilly USA, LLC LLY | 1 | $46.05 |
| Insmed, Inc. INSM | 2 | $44.19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $40.28 |
| Amgen Inc. AMGN | 2 | $39.92 |
| Actelion Pharmaceuticals US, Inc. JNJ | 1 | $35.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.